Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Simeng LinNeil ChanchlaniIsabel CarberyMalik JanjuaRachel NiceTimothy James McDonaldClaire M BewsheaNicholas Alexander KennedyTariq AhmadChristian Philipp SelingerJames R Goodhandnull nullPublished in: Alimentary pharmacology & therapeutics (2022)
Lower baseline serum fT3/fT4 ratio was associated with female sex, corticosteroid use and disease activity. It predicted PNR to anti-TNF treatment at week 14, but not non-remission at week 54.